Department of Anesthesiology, Tohoku University Hospital, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan.
Department of Physiology, Tohoku University Graduate School of Medicine, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan.
Biomed Res Int. 2019 Apr 30;2019:6261951. doi: 10.1155/2019/6261951. eCollection 2019.
BACKGROUND/AIMS: Voltage-dependent potassium channels (Kv1.3) are predominantly expressed in lymphocyte plasma membranes. These channels are critical for the activation and proliferation of lymphocytes. Since second-generation antihistamines are lipophilic and exert immunomodulatory effects, they are thought to affect the lymphocyte Kv1.3-channel currents.
Using the patch-clamp whole-cell recording technique in murine thymocytes, we tested the effects of second-generation antihistamines, such as cetirizine, fexofenadine, azelastine, and terfenadine, on the channel currents and the membrane capacitance.
These drugs suppressed the peak and the pulse-end currents of the channels, although the effects of azelastine and terfenadine on the peak currents were more marked than those of cetirizine and fexofenadine. Both azelastine and terfenadine significantly lowered the membrane capacitance. Since these drugs did not affect the process of endocytosis in lymphocytes, they were thought to have interacted directly with the plasma membranes.
Our study revealed for the first time that second-generation antihistamines, including cetirizine, fexofenadine, azelastine, and terfenadine, exert suppressive effects on lymphocyte Kv1.3-channels. The efficacy of these drugs may be related to their immunomodulatory mechanisms that reduce the synthesis of inflammatory cytokine.
背景/目的:电压门控钾通道(Kv1.3)主要表达于淋巴细胞质膜上。这些通道对淋巴细胞的激活和增殖至关重要。由于第二代抗组胺药具有亲脂性并发挥免疫调节作用,因此它们被认为会影响淋巴细胞 Kv1.3 通道电流。
我们使用全细胞膜片钳记录技术在鼠胸腺细胞中检测了第二代抗组胺药,如西替利嗪、非索非那定、氮卓斯汀和特非那定,对通道电流和膜电容的影响。
这些药物抑制了通道的峰值和脉冲结束电流,尽管氮卓斯汀和特非那定对峰值电流的作用比西替利嗪和非索非那定更为显著。氮卓斯汀和特非那定均显著降低了膜电容。由于这些药物不影响淋巴细胞内吞作用的过程,因此它们被认为直接与质膜相互作用。
我们的研究首次揭示,第二代抗组胺药,包括西替利嗪、非索非那定、氮卓斯汀和特非那定,对淋巴细胞 Kv1.3 通道具有抑制作用。这些药物的疗效可能与其免疫调节机制有关,即减少炎症细胞因子的合成。